Werewolf Therapeutics (NASDAQ:HOWL) is performing incredibly well today with its stock trading for the first day after its initial public offering (IPO). Source: Shutterstock The first day of trading ...

One of the biggest complaints about modern horror movies is that it's much more cost-effective and much faster to rely on digital effects as opposed to practical effects. No matter how sophisticated ...

Werewolf Therapeutics (NASDAQ:HOWL) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company ...

Werewolf Therapeutics, Inc. (HOWL Quick Quote HOWL - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an ...

) has been revised to $7.14 / share. This is an increase of 12.00% from the prior estimate of $6.38 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Werewolf Therapeutics, Inc. (HOWL Quick Quote HOWL - Free Report) reports results for the quarter ended March 2025.

Sure, we've all seen "Teen Wolf" and "An American Werewolf in London." But these five underrated werewolf movies are also a ...

Add Yahoo as a preferred source to see more of our stories on Google. Cinematically, werewolf movies have often been told as coming-of-age sagas that serve as allegories for life changes and rites of ...

A few weeks back you might recall that we gave you the first heads up on a new werewolf film on the horizon called Howl (“Fever Pitch Ready to Howl” – November 2007). Since that story went up, ...